SynthesisJournal of neuro-oncology2026
Hormone therapy and the risk of central nervous system tumors in women: a systematic review and meta-analysis.
Synthesis in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHormone therapy is widely used for contraception, disease treatment, and as hormone replacement therapy in women. Many studies have attempted to establish the relationship between the use of exogenous hormones and the development of CNS tumors; however, the results remain inconclusive.
objectivesThe objective of this meta-analysis is to evaluate the association between hormone therapy use and the risk of developing central nervous system (CNS) tumors, particularly meningioma and glioma.
methodsPubMed, Scopus, and Web of Science databases were searched for studies reporting the association between hormone therapy use and CNS tumor risk. The outcomes analyzed were overall risk for CNS tumors, meningioma, and glioma, described as odds ratios (ORs) and hazard ratios (HRs). Statistical analyses were performed using R (version 4.4.2), with a significance level of p < 0.05.
resultsThe analysis of the 19 studies involving 2.398.681 patients demonstrated a significant association between hormone therapy use and the overall risk of CNS tumors (OR = 1.69; 95% CI, 1.28–2.23; p < 0.001; I² = 98.5%). Subgroup analysis revealed an increased risk for the development of meningioma (OR = 2.10; 95% CI, 1.52–2.91; I² = 98.6%), whereas for gliomas the exposure may not be associated with an increased risk (OR = 0.90; 95% CI, 0.64–1.27; I² = 84.9%). The overall risk of CNS tumors was also expressed using hazard ratios (HR = 1.18; 95% CI, 0.97–1.45; p = 0.097; I² = 71.0%), showing an insignificant trend favoring non-use of hormone therapy, with an increased risk observed for meningioma (HR = 1.59; 95% CI, 1.09–2.32; I² = 72.8%), while based on the analyzed data, hormone therapy use may not appear to increase the risk of glioma development (HR = 0.99; 95% CI, 0.86–1.16; I² = 36%).
conclusionThis meta-analysis suggests that exogenous hormonal therapy is associated with an increased risk of central nervous system tumors in women, driven predominantly by meningioma risk. No consistent association was observed for glioma.
Indexed as
Identifiers
41721900What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.